Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence...

Area of Science:

• Oncology
• Pharmacology
• Regulatory Science

Background:

• Since 2011, 30 new drugs, primarily tyrosine kinase and immune checkpoint inhibitors, have been approved by the US FDA for advanced non-small cell lung cancer (NSCLC).
• Drug development and approval pathways diverge for NSCLC subtypes with oncogene driver alterations versus those without.

Purpose of the Study:

• To analyze novel therapeutic approval patterns for NSCLC.
• To focus on small-molecule inhibitors targeting driver alterations and biologics, including monoclonal antibodies and antibody-drug conjugates.
• To examine how NSCLC subtype differentiation influences drug development and regulatory strategies.

Main Methods:

• Review of US FDA drug approvals for advanced NSCLC since 2011.
• Analysis of drug classes, including small-molecule inhibitors, monoclonal antibodies targeting PD-(L)1 or cell surface receptors, and antibody-drug conjugates.
• Categorization of NSCLC into oncogene-addicted and non-oncogene-addicted subtypes.

Main Results:

• Accelerated approval based on high response rates for NSCLC with driver alterations, confirmed by postmarketing trials.
• Randomized controlled trial designs are prioritized for NSCLC without driver alterations, focusing on survival or event-free survival.
• Approval strategies, clinical development scope, and access to incentives are determined by NSCLC subtype.

Conclusions:

• The classification of NSCLC into oncogene-addicted and non-oncogene-addicted subtypes is critical for tailoring drug development and regulatory pathways.
• Targeted small-molecule inhibitors and biologics represent key therapeutic advances for NSCLC.
• Regulatory agencies set distinct evidence expectations based on NSCLC molecular characteristics.